Table 2. Characteristics After Transplant.
| Characteristic | No./total No. (%) | |||||
|---|---|---|---|---|---|---|
| Myeloid cohort (n = 53) | Lymphoid cohort (n = 53) | |||||
| HLA loss group | Classic group | P value | HLA loss group | Classic group | P value | |
| Total | 29/53 (54.7) | 24/53 (45.3) | NA | 25/53 (47.2) | 28/53 (52.8) | NA |
| De novo acute GVHD | 16/22 (72.7) | 6/22 (27.3) | .03 | 12/25 (48.0) | 13/25 (52.0) | .91 |
| Time from HSCT to acute GVHD occurrence, median (range), d | 25 (9-206) | 38 (7-136) | .54 | 44 (5-166) | 28 (7-228) | .69 |
| Chronic GVHD | 15/20 (75.0) | 5/20 (25.0) | .02 | 8/9 (88.9) | 1/9 (11.1) | .009 |
| Time from HSCT to chronic GVHD occurrence, median (range), d | 189 (119-1120) | 197 (56-429) | >.99 | 189 (126-801) | 657 (657-657) | .44 |
| DLI before relapse | 16/25 (64.0) | 9/25 (36.0) | .20 | 6/9 (66.7) | 3/9 (33.3) | .28 |
| Cumulative CD3+ cells by DLI, median (range), ×107/kg | 2.0 (0.1-5.8) | 1.5 (0.3-6.6) | .61 | 1.9 (1.0-2.8) | 1.1 (1.0-1.8) | .30 |
| MRD-positivity before relapse | 17/28 (60.7) | 11/28 (39.3) | .35 | 7/10 (70.0) | 3/10 (30.0) | .16 |
| Time from HSCT to relapse, median (range), y | 321 (55-1574) | 223 (68-546) | .03 | 323 (98-2056) | 151 (57-2544) | .01 |
| BM blasts ratio at relapse, median (range) | 0.16 (0.01-0.89) | 0.28 (0.06-0.92) | .04 | 0.40 (0-0.90) | 0.30 (0-0.90) | .99 |
| EMD at relapse | 3/5 (60.0) | 2/5 (40.0) | >.99 | 11/16 (68.8) | 5/16 (31.3) | .04 |
Abbreviations: BM, bone marrow; DLI, donor lymphocyte infusion; EMD, extramedullary disease; GVHD, graft-vs-host disease; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplant; MRD, minimal residual disease; NA, not applicable.